It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
The Ma’anshan site approval covers pastilles, oral liquids, and powders
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
This project shall be implemented through incorporation of a new joint venture company in Zambia
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
This certification will open new markets for the Kwality Pharma
Exploring new opportunities within the fast-growing market of microfluidics
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Subscribe To Our Newsletter & Stay Updated
